DNDN

May 22, 2012

MD Becker Partners' newsletter covering the life science industry

Rethinking Immunotherapy for Brain Tumors

February 22, 2012 By MD Becker Partners Leave a Comment

Eight companies with immunotherapy approaches for brain tumors

Filed Under: Articles Tagged With: AGEN, Agenus, astrocytoma, biotechnology, brain cancer, Celldex Therapeutics, CLDX, Dendreon, dendritic cell, DNDN, GBM, GlaxoSmithKline, Glioblastoma multiforme, glioma, GSK, heat-shock protein, HSPPC-96, Immatics Biotechnologies, immunotherapy, IMUC, Innocell Corp, JNJ, Johnson & Johnson, mmunoCellular Therapeutics, Northwest Biotherapeutics, NWBO, Oncovir, prophage, TVAX Biomedical

2011 Review and Outlook for Biotechnology in 2012

January 25, 2012 By MD Becker Partners Leave a Comment

Our favorable outlook for the biotechnology industry remains intact for 2012 and is based on several key drivers

Filed Under: Articles Tagged With: 2011, 2012, Access to Capital, Akorn, AKRX, BDSI, BioDelivery Sciences, biotechnology, BMY, Bristol-Myers Squibb, Canaan Partners, consolidation, defensive sector, Dendreon, DNDN, Economic Driver, Endo Pharmaceuticals, ENDP, FDA, Flagship Ventures, HGSI, Human Genome Sciences, Inc., Inhibitex, INHX, ISTA, ISTA Pharmaceuticals, M&A, MDVN, Medivation, NASDAQ, New Drug Approvals, outlook, PhRMA, Pipeline, Review, RHHBY, roche, Valeant Pharmaceuticals, Vivo Ventures, VRX, Xenon Pharmaceuticals

2012 Preview: Cancer Immunotherapy Catalysts

December 14, 2011 By MD Becker Partners 1 Comment

MD Becker Partners' Life Science Digest: 2012 graphic

2012 represents a period with robust news flow for emerging immuno-oncology companies

Filed Under: Articles Tagged With: AE37, AGEN, Agenus, Allovectin, Amgen, AMGN, Antigen Express, BAVA, Bavarian Nordic, BMY, Bristol-Myers Squibb, cancer vaccine, castrate-resistant prostate cancer, CELG, Celgene, Celldex Therapeutics, CLDX, cv-301, Dendreon, DNDN, Generex, GlaxoSmithKline, GlobeImmune, GNBT, gp100, GSK, HyperAcute, Idera Pharmaceuticals, IDRA, immunotherapy, IMO-2055, ipilimumab, Jennerex, JX-594, MAGE-A3, melanoma, NewLink Genetics, NLNK, NSCLC, Oncothyreon, OncoVex, ONTY, pancreatic cancer, panvac, PROSTVAC, Provenge, QS-21, sipuleucel-T, Stimuvax, TG4010, transgene, Vical, VICL, Yervoy

Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution

September 18, 2011 By MD Becker Partners Leave a Comment

MD Becker Partners' Life Science Digest: Adjuvants

Often overlooked, adjuvants can be an essential part of an effective vaccine and could help advance the field of cancer immunotherapy even further.

Filed Under: Articles Tagged With: 3M Company, adjuvant, AE37, AGEN, Agenus, aluminum salts, Antigen Express, antigen-specific cancer immunotherapeutic, AS15, BARDA, Biomedical Advanced Research and Development Authority, BMY, Bristol-Myers Squibb, cancer immunotherapy, Cationic Lipid-DNA Complex, CDX-1401, Celldex Therapeutics, Cervarix, CLDX, Colby Pharmaceutical Company, Corixa Corporation, CpG, CyMVectin, Dendreon Corporation, DNDN, Generex Biotechnology, GLA, GlaxoSmithKline, glucopyranosyl lipid A, GNBT, GSK, Idera Pharmaceuticals, IDRA, Ii-Key hybrid technology, Immune Design Corporation, IMO-2055, ipilimumab, Juvaris BioTherapeutics, JVRS-100, MAGE-A3, MF59, MMM, monophosphoryl lipid A, Mosquirix, MPL, pandemic influenza, Provenge, QS-21, Quillaja saponaria, resiquimod, saponin, sipuleucel-T, squalene, TLR, toll-like receptor, Vaxfectin, Vical Inc., VICL, Yervoy

Similarities Between Two Immunotherapies in Cancer

March 30, 2011 By MD Becker Partners 1 Comment

Approval of Bristol-Myers Squibb’s Yervoy® [ipilimumab] for melanoma in March 2011 marked the second victory for the field of immunotherapy in oncology within a year.

Filed Under: Articles Tagged With: Abiraterone acetate, active immunotherapy, Astellas, BAVA.CO, Bavarian Nordic, biotechnology, BMY, Bristol-Myers Squibb Company, cancer vaccine, Dendreon Corporation, DNDN, docetaxel, FDA, Inc., ipilimumab, JNJ, Johnson & Johnson, MDV3100, MDVN, Medivation, melanoma, oncology, Plexxikon, PLX4032, prostate cancer, PROSTVAC, Provenge, roche, sipuleucel-T, Taxotere, Yervoy

Rethinking Immunotherapy for Brain Tumors

2011 Review and Outlook for Biotechnology in 2012

2012 Preview: Cancer Immunotherapy Catalysts

Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution

Similarities Between Two Immunotherapies in Cancer

Download the Life Science Digest App

Featured Video

About Life Science Digest

Like Us on Facebook

Rethinking Immunotherapy for Brain Tumors

2011 Review and Outlook for Biotechnology in 2012

2012 Preview: Cancer Immunotherapy Catalysts

Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution

Similarities Between Two Immunotherapies in Cancer

Download the Life Science Digest App

Follow MD Becker Partners

Featured Video

About Life Science Digest

Article Tag Cloud

Like Us on Facebook